Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Structure-activity relationship study of NPP1 inhibitors based on uracil-N1-(methoxy)ethyl-β-phosphate scaffold.

Nassir M, Pelletier J, Arad U, Arguin G, Khazanov N, Gendron FP, Sévigny J, Senderowitz H, Fischer B.

Eur J Med Chem. 2019 Oct 4;184:111754. doi: 10.1016/j.ejmech.2019.111754. [Epub ahead of print]

PMID:
31610377
2.

Novel inhibitors of leukocyte transendothelial migration.

Getter T, Margalit R, Kahremany S, Levy L, Blum E, Khazanov N, Keshet-Levy NY, Tamir TY, Ben Major M, Lahav R, Zilber S, Senderowitz H, Bradfield P, Imhof BA, Alpert E, Gruzman A.

Bioorg Chem. 2019 Sep 9;92:103250. doi: 10.1016/j.bioorg.2019.103250. [Epub ahead of print]

PMID:
31580982
3.

Hsp104 facilitates the endoplasmic-reticulum-associated degradation of disease-associated and aggregation-prone substrates.

Doonan LM, Guerriero CJ, Preston GM, Buck TM, Khazanov N, Fisher EA, Senderowitz H, Brodsky JL.

Protein Sci. 2019 Jul;28(7):1290-1306. doi: 10.1002/pro.3636. Epub 2019 May 20.

PMID:
31050848
4.

Guaiacol as a drug candidate for treating adult polyglucosan body disease.

Kakhlon O, Ferreira I, Solmesky LJ, Khazanov N, Lossos A, Alvarez R, Yetil D, Pampou S, Weil M, Senderowitz H, Escriba P, Yue WW, Akman HO.

JCI Insight. 2018 Sep 6;3(17). pii: 99694. doi: 10.1172/jci.insight.99694. eCollection 2018 Sep 6.

5.

The Q359K/T360K mutation causes cystic fibrosis in Georgian Jews.

Mei-Zahav M, Stafler P, Senderowitz H, Bentur L, Livnat G, Shteinberg M, Orenstein N, Bazak L, Prais D, Levine H, Gur M, Khazanov N, Simhaev L, Eliyahu H, Cohen M, Wilschanski M, Blau H, Mussaffi H.

J Cyst Fibros. 2018 Sep;17(5):e41-e45. doi: 10.1016/j.jcf.2018.06.008. Epub 2018 Jul 20.

PMID:
30033373
6.

Ligand binding to a remote site thermodynamically corrects the F508del mutation in the human cystic fibrosis transmembrane conductance regulator.

Wang C, Aleksandrov AA, Yang Z, Forouhar F, Proctor EA, Kota P, An J, Kaplan A, Khazanov N, Boël G, Stockwell BR, Senderowitz H, Dokholyan NV, Riordan JR, Brouillette CG, Hunt JF.

J Biol Chem. 2018 Nov 16;293(46):17685-17704. doi: 10.1074/jbc.RA117.000819. Epub 2018 Jun 14.

PMID:
29903914
7.

Structural stability of purified human CFTR is systematically improved by mutations in nucleotide binding domain 1.

Yang Z, Hildebrandt E, Jiang F, Aleksandrov AA, Khazanov N, Zhou Q, An J, Mezzell AT, Xavier BM, Ding H, Riordan JR, Senderowitz H, Kappes JC, Brouillette CG, Urbatsch IL.

Biochim Biophys Acta Biomembr. 2018 May;1860(5):1193-1204. doi: 10.1016/j.bbamem.2018.02.006. Epub 2018 Feb 7.

8.

A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease.

Solmesky LJ, Khazanov N, Senderowitz H, Wang P, Minassian BA, Ferreira IM, Yue WW, Lossos A, Weil M, Kakhlon O.

Biochem J. 2017 Sep 28;474(20):3403-3420. doi: 10.1042/BCJ20170469.

9.

Specific stabilization of CFTR by phosphatidylserine.

Hildebrandt E, Khazanov N, Kappes JC, Dai Q, Senderowitz H, Urbatsch IL.

Biochim Biophys Acta Biomembr. 2017 Feb;1859(2):289-293. doi: 10.1016/j.bbamem.2016.11.013. Epub 2016 Nov 30.

10.

Plant phenolic volatiles inhibit quorum sensing in pectobacteria and reduce their virulence by potential binding to ExpI and ExpR proteins.

Joshi JR, Khazanov N, Senderowitz H, Burdman S, Lipsky A, Yedidia I.

Sci Rep. 2016 Dec 1;6:38126. doi: 10.1038/srep38126.

11.

Potentiators exert distinct effects on human, murine, and Xenopus CFTR.

Cui G, Khazanov N, Stauffer BB, Infield DT, Imhoff BR, Senderowitz H, McCarty NA.

Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L192-207. doi: 10.1152/ajplung.00056.2016. Epub 2016 Jun 10.

12.

Design of Compact Biomimetic Cellulose Binding Peptides as Carriers for Cellulose Catalytic Degradation.

Khazanov N, Iline-Vul T, Noy E, Goobes G, Senderowitz H.

J Phys Chem B. 2016 Jan 21;120(2):309-19. doi: 10.1021/acs.jpcb.5b11050. Epub 2016 Jan 6.

PMID:
26691055
13.

Next generation sequencing technologies reveal the tumor-associated somatic mutation profile.

Sadis S, Williams P, Khazanov N.

MLO Med Lab Obs. 2014 Feb;46(2):32, 34. No abstract available.

PMID:
24672851
14.

Exploring the composition of protein-ligand binding sites on a large scale.

Khazanov NA, Carlson HA.

PLoS Comput Biol. 2013;9(11):e1003321. doi: 10.1371/journal.pcbi.1003321. Epub 2013 Nov 21.

15.

Asymmetric DNA-search dynamics by symmetric dimeric proteins.

Khazanov N, Marcovitz A, Levy Y.

Biochemistry. 2013 Aug 13;52(32):5335-44. doi: 10.1021/bi400357m. Epub 2013 Jul 31.

PMID:
23866074
16.

Identification of targetable FGFR gene fusions in diverse cancers.

Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM.

Cancer Discov. 2013 Jun;3(6):636-47. doi: 10.1158/2159-8290.CD-13-0050. Epub 2013 Apr 4.

17.

Overcoming sequence misalignments with weighted structural superposition.

Khazanov NA, Damm-Ganamet KL, Quang DX, Carlson HA.

Proteins. 2012 Nov;80(11):2523-35. doi: 10.1002/prot.24134. Epub 2012 Jul 28.

18.

CSAR benchmark exercise of 2010: selection of the protein-ligand complexes.

Dunbar JB Jr, Smith RD, Yang CY, Ung PM, Lexa KW, Khazanov NA, Stuckey JA, Wang S, Carlson HA.

J Chem Inf Model. 2011 Sep 26;51(9):2036-46. doi: 10.1021/ci200082t. Epub 2011 Jul 22. Erratum in: J Chem Inf Model. 2011Sep 26;51(9):2146.

19.

Sliding of p53 along DNA can be modulated by its oligomeric state and by cross-talks between its constituent domains.

Khazanov N, Levy Y.

J Mol Biol. 2011 Apr 29;408(2):335-55. doi: 10.1016/j.jmb.2011.01.059. Epub 2011 Feb 19.

PMID:
21338609
20.

The mechanism of papain inhibition by peptidyl aldehydes.

Shokhen M, Khazanov N, Albeck A.

Proteins. 2011 Mar;79(3):975-85. doi: 10.1002/prot.22939. Epub 2010 Dec 22.

PMID:
21181719
21.

Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults.

Mauer AC, Khazanov NA, Levenkova N, Tian S, Barbour EM, Khalida C, Tobin JN, Coller BS.

J Thromb Haemost. 2011 Jan;9(1):100-8. doi: 10.1111/j.1538-7836.2010.04105.x.

22.

Creating an ontology-based human phenotyping system: The Rockefeller University bleeding history experience.

Mauer AC, Barbour EM, Khazanov NA, Levenkova N, Mollah SA, Coller BS.

Clin Transl Sci. 2009 Oct;2(5):382-5. doi: 10.1111/j.1752-8062.2009.00147.x.

23.

Challenging a paradigm: theoretical calculations of the protonation state of the Cys25-His159 catalytic diad in free papain.

Shokhen M, Khazanov N, Albeck A.

Proteins. 2009 Dec;77(4):916-26. doi: 10.1002/prot.22516.

24.

Differences between high- and low-affinity complexes of enzymes and nonenzymes.

Carlson HA, Smith RD, Khazanov NA, Kirchhoff PD, Dunbar JB Jr, Benson ML.

J Med Chem. 2008 Oct 23;51(20):6432-41. doi: 10.1021/jm8006504. Epub 2008 Oct 1.

25.

Binding MOAD, a high-quality protein-ligand database.

Benson ML, Smith RD, Khazanov NA, Dimcheff B, Beaver J, Dresslar P, Nerothin J, Carlson HA.

Nucleic Acids Res. 2008 Jan;36(Database issue):D674-8. Epub 2007 Nov 30.

26.
27.
28.

Enzyme isoselective inhibitors: application to drug design.

Shokhen M, Khazanov N, Albeck A.

ChemMedChem. 2006 Jun;1(6):639-43.

PMID:
16892404
29.

Enzyme isoselective inhibitors: a tool for binding-trend analysis.

Ozeri R, Khazanov N, Perlman N, Shokhen M, Albeck A.

ChemMedChem. 2006 Jun;1(6):631-8.

PMID:
16892403

Supplemental Content

Loading ...
Support Center